DR. REDDY’S LABORATORIES
Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas. Dr. Reddy’s originally launched in 1984 producing active pharmaceutical ingredients.
Good Health’ is always their goal. They see medicines not just as molecules, but as means to help patients regain their health. As a leader in the pharmaceutical industry, they realize their unique role; they have the ethical and moral imperative to ensure good health can be delivered to those who need it, and to promote wellness among them. The company’s belief is guided by their principles – Empathy and Dynamism – which provide both guidance for their current behaviour and inspiration for their future actions.
COVID-19 RESPONSE:
As an organization responsible for producing essential drugs, they have ensured operational continuity in order to serve patient needs, without compromising the health and safety of our employees and their families. The company has also ensured the availability of PPE kits across locations. The company initiated the KeepSafe app by their IT team with Bluetooth and GPS enabled features to facilitate easy tracking of COVID-19 positive cases across their plants and offices. They also extended their health insurance coverage to an additional ₹ 0.3 million per person (including pre-covered family members) for COVID-19.
They donated 300,000+ N-95 masks, 100,000+ pairs of gloves, 10,000+ bottles of sanitizers and Hydroxychloroquine tablets to medical professionals, public servants and healthcare institutions across India. The company made monetary donations of ₹ 50 million to the Government of Telangana to enable access to N95 masks for frontline health workers in the state, along with a contribution of ₹ 50 million towards the Andhra Pradesh CM Relief Fund.
Their shareholding pattern consists of Promoters and Promoter Group having 26.73% of shares, Public having 28.17% shares, following by FII’s having 29.04% shares and DII’s with 15.74% shares, Non Promoters – Non Public having 0.32%.
